Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenlin Ju

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Oncotarget|January 2, 2018
Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patientsKaren Klepsland Mauland, Zhenlin Ju, Ingvild Løberg Tangen, et al.
Cancer Cell|October 7, 2014
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitorsLydia W T Cheung, Shuangxing Yu, Dong Zhang, et al.
Nature Methods|September 17, 2013
TCPA: a resource for cancer functional proteomics dataJun Li, Yiling Lu, Rehan Akbani, et al.
Plos One|October 7, 2020
Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNANoriyuki Sasaki, Takeshi Iwaya, Takehiro Chiba, et al.
Cancer Discovery|June 13, 2015
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsJianfeng Shen, Yang Peng, Leizhen Wei, et al.
The Journal of Clinical Investigation|October 5, 2020
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsLulu Wang, Lin Yang, Chen Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaMichael A Davies, Katherine Stemke-Hale, E Lin, et al.
Oncotarget|June 14, 2019
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy optionsMarilyne Labrie, Tae-Beom Kim, Zhenlin Ju, et al.
British Journal of Cancer|March 4, 2021
Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profilingMizunori Yaegashi, Takeshi Iwaya, Noriyuki Sasaki, et al.
Molecular & Cellular Proteomics : MCP|March 14, 2018
Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded AntibodiesJinho Lee, Gary K Geiss, Gokhan Demirkan, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Oncotarget|January 2, 2018
Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patientsKaren Klepsland Mauland, Zhenlin Ju, Ingvild Løberg Tangen, et al.
Cancer Cell|October 7, 2014
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitorsLydia W T Cheung, Shuangxing Yu, Dong Zhang, et al.
Nature Methods|September 17, 2013
TCPA: a resource for cancer functional proteomics dataJun Li, Yiling Lu, Rehan Akbani, et al.
Plos One|October 7, 2020
Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNANoriyuki Sasaki, Takeshi Iwaya, Takehiro Chiba, et al.
Cancer Discovery|June 13, 2015
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsJianfeng Shen, Yang Peng, Leizhen Wei, et al.
The Journal of Clinical Investigation|October 5, 2020
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsLulu Wang, Lin Yang, Chen Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaMichael A Davies, Katherine Stemke-Hale, E Lin, et al.
Oncotarget|June 14, 2019
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy optionsMarilyne Labrie, Tae-Beom Kim, Zhenlin Ju, et al.
British Journal of Cancer|March 4, 2021
Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profilingMizunori Yaegashi, Takeshi Iwaya, Noriyuki Sasaki, et al.
Molecular & Cellular Proteomics : MCP|March 14, 2018
Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded AntibodiesJinho Lee, Gary K Geiss, Gokhan Demirkan, et al.
Pageof 9